Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study-Reference-Cited by-同舟云学术

Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study

Published:2014-03-11 Issue:2 Volume:7 Page:84-92
ISSN:1757-5664
Container-title:LUTS: Lower Urinary Tract Symptoms
language:en
Short-container-title:Lower Urinary Tract Symptoms

Author:

YAMAGUCHI Osamu¹,MARUI Eiji²,IGAWA Yasuhiko³,TAKEDA Masayuki⁴,NISHIZAWA Osamu⁵,IKEDA Yasushi⁶,OHKAWA Sumito⁶

Affiliation:

1. Division of Bioengineering and LUTD Research; School of Engineering, Nihon University; Koriyama Japan

2. Department of Human Arts Sciences; University and Graduate School of Human Arts Sciences; Saitama Japan

3. Department of Continence Medicine; The University of Tokyo Graduate School of Medicine; Tokyo Japan

4. Department of Urology; University of Yamanashi; Yamanashi Japan

5. Department of Urology; Shinshu University; Matsumoto Japan

6. Astellas Pharma Inc; Tokyo Japan

Funder

Astellas Pharma Inc

Publisher

Wiley

Subject

Urology,Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/luts.12053/fullpdf

Reference16 articles.

1. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society;Abrams;Urology,2003

2. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment;Brubaker;Urology,2006

3. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study;Coyne;BJU Int,2008

4. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study;Milsom;BJU Int,2001

5. Epidemiologic survey on lower urinarytract symptoms in Japan;Homma;J Jpn Neurogenic Bladder Soc.,2003

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2024 Revised Dutch guidelines for urinary incontinence: Addressing clinical bottlenecks through a modular approach;Continence;2024-12

2. Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials;Frontiers in Surgery;2024-08-26

3. The impact of pharmacotherapy on sexual function in female patients being treated for idiopathic overactive bladder: a systematic review;BMC Women's Health;2024-05-16

4. Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database;Frontiers in Pharmacology;2024-03-18

5. Examining the Safety of Mirabegron: An Analysis of Real-World Pharmacovigilance Data from the US FDA Adverse Event Reporting System (FAERS) Database;2024-01-03